271 related articles for article (PubMed ID: 34767457)
1. Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape.
Takeuchi Y; Tanegashima T; Sato E; Irie T; Sai A; Itahashi K; Kumagai S; Tada Y; Togashi Y; Koyama S; Akbay EA; Karasaki T; Kataoka K; Funaki S; Shintani Y; Nagatomo I; Kida H; Ishii G; Miyoshi T; Aokage K; Kakimi K; Ogawa S; Okumura M; Eto M; Kumanogoh A; Tsuboi M; Nishikawa H
Sci Immunol; 2021 Nov; 6(65):eabc6424. PubMed ID: 34767457
[TBL] [Abstract][Full Text] [Related]
2. Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.
Wall JA; Meza-Perez S; Scalise CB; Katre A; Londoño AI; Turbitt WJ; Randall T; Norian LA; Arend RC
Gynecol Oncol; 2021 Jan; 160(1):285-294. PubMed ID: 33168307
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β-catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody.
Katoh Y; Yaguchi T; Kubo A; Iwata T; Morii K; Kato D; Ohta S; Satomi R; Yamamoto Y; Oyamada Y; Ouchi K; Takahashi S; Ishioka C; Matoba R; Suematsu M; Kawakami Y
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793868
[TBL] [Abstract][Full Text] [Related]
4. Newly emerged immunogenic neoantigens in established tumors enable hosts to regain immunosurveillance in a T-cell-dependent manner.
Muramatsu T; Noguchi T; Sugiyama D; Kanada Y; Fujimaki K; Ito S; Gotoh M; Nishikawa H
Int Immunol; 2021 Jan; 33(1):39-48. PubMed ID: 32729901
[TBL] [Abstract][Full Text] [Related]
5. Intrinsic β-catenin signaling suppresses CD8
Xue J; Yu X; Xue L; Ge X; Zhao W; Peng W
Biomed Pharmacother; 2019 Jul; 115():108921. PubMed ID: 31078045
[TBL] [Abstract][Full Text] [Related]
6. CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in Egfr-Mutant Lung Cancer.
Nishii K; Ohashi K; Tomida S; Nakasuka T; Hirabae A; Okawa S; Nishimura J; Higo H; Watanabe H; Kano H; Ando C; Makimoto G; Ninomiya K; Kato Y; Kubo T; Ichihara E; Hotta K; Tabata M; Toyooka S; Udono H; Maeda Y; Kiura K
Cancer Immunol Res; 2022 Sep; 10(9):1111-1126. PubMed ID: 35802887
[TBL] [Abstract][Full Text] [Related]
7. E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling.
Yamada K; Hori Y; Inoue S; Yamamoto Y; Iso K; Kamiyama H; Yamaguchi A; Kimura T; Uesugi M; Ito J; Matsuki M; Nakamoto K; Harada H; Yoneda N; Takemura A; Kushida I; Wakayama N; Kubara K; Kato Y; Semba T; Yokoi A; Matsukura M; Odagami T; Iwata M; Tsuruoka A; Uenaka T; Matsui J; Matsushima T; Nomoto K; Kouji H; Owa T; Funahashi Y; Ozawa Y
Cancer Res; 2021 Feb; 81(4):1052-1062. PubMed ID: 33408116
[TBL] [Abstract][Full Text] [Related]
8. PD-1 blockade augments CD8
Nakasuka T; Ohashi K; Nishii K; Hirabae A; Okawa S; Tomonobu N; Takada K; Ando C; Watanabe H; Makimoto G; Ninomiya K; Fujii M; Kubo T; Ichihara E; Hotta K; Tabata M; Kumon H; Maeda Y; Kiura K
Lung Cancer; 2023 Apr; 178():1-10. PubMed ID: 36753780
[TBL] [Abstract][Full Text] [Related]
9. CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer.
Zhang M; Yang W; Wang P; Deng Y; Dong YT; Liu FF; Huang R; Zhang P; Duan YQ; Liu XD; Lin D; Chu Q; Zhong B
Nat Commun; 2020 Nov; 11(1):6119. PubMed ID: 33257678
[TBL] [Abstract][Full Text] [Related]
10. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
[TBL] [Abstract][Full Text] [Related]
11. WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment.
Li X; Xiang Y; Li F; Yin C; Li B; Ke X
Front Immunol; 2019; 10():2293. PubMed ID: 31616443
[TBL] [Abstract][Full Text] [Related]
12. Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity.
Tanegashima T; Togashi Y; Azuma K; Kawahara A; Ideguchi K; Sugiyama D; Kinoshita F; Akiba J; Kashiwagi E; Takeuchi A; Irie T; Tatsugami K; Hoshino T; Eto M; Nishikawa H
Clin Cancer Res; 2019 Aug; 25(15):4808-4819. PubMed ID: 31076547
[TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.
Liu SY; Dong ZY; Wu SP; Xie Z; Yan LX; Li YF; Yan HH; Su J; Yang JJ; Zhou Q; Zhong WZ; Tu HY; Yang XN; Zhang XC; Wu YL
Lung Cancer; 2018 Nov; 125():86-92. PubMed ID: 30429043
[TBL] [Abstract][Full Text] [Related]
14. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
15. The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration.
Perea F; Bernal M; Sánchez-Palencia A; Carretero J; Torres C; Bayarri C; Gómez-Morales M; Garrido F; Ruiz-Cabello F
Int J Cancer; 2017 Feb; 140(4):888-899. PubMed ID: 27785783
[TBL] [Abstract][Full Text] [Related]
16. Asiaticoside promoted ferroptosis and suppressed immune escape in gastric cancer cells by downregulating the Wnt/β-catenin pathway.
Ye C; Yao Z; Wang Y; Zhang C
Int Immunopharmacol; 2024 Jun; 134():112175. PubMed ID: 38733821
[TBL] [Abstract][Full Text] [Related]
17. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
18. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y
Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade.
Lin C; Ren W; Luo Y; Li S; Chang Y; Li L; Xiong D; Huang X; Xu Z; Yu Z; Wang Y; Zhang J; Huang C; Xia N
Cancer Immunol Res; 2020 May; 8(5):632-647. PubMed ID: 32127389
[TBL] [Abstract][Full Text] [Related]
20. CD8
Huang B; Liu R; Wang P; Yuan Z; Yang J; Xiong H; Zhang N; Huang Q; Fu X; Sun W; Li L
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32606053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
